News Article

Navidea Biopharmaceuticals Announces Issuance of New U.S. Patent Covering Formulation for Neuroimaging Agent, NAV5001
Date: Nov 14, 2013
Source: ( click here to go to the source)

Featured firm in this article: Navidea Biopharmaceuticals Inc of Dublin, OH

DUBLIN, Ohio--(BUSINESS WIRE)--Nov. 14, 2013-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering the formulation of the Company's radiolabeled dopamine transporter (DAT) receptor ligand, NAV5001, used with SPECT imaging for potential differential diagnosis of Parkinsonian Syndromes and Dementia with Lewy Bodies. The patent (8,574,545) is set to expire in 2031.

The new U.S. patent, "Labeled Iodinated Tropane Formulation," extends the scope and longevity of the NAV5001 intellectual property (IP) portfolio. The high concentration formulation protected by this patent may afford greater commercial flexibility and manufacturing efficiency to optimize distribution. Navidea anticipates commencing the NAV5001 Phase 3 clinical program by year end. This new patent reinforces the Company's NAV5001 platform alongside previously issued U.S. Patent 8,084,018, "Methods for Imaging Dopamine Transporter Level," which covers the acquisition of Dopamine Transporter SPECT images soon after injection of NAV5001, a unique feature and competitive advantage for NAV5001. These patents were issued to Alseres Pharmaceuticals and have been licensed exclusively to Navidea.